IL254320A0 - organic compounds - Google Patents

organic compounds

Info

Publication number
IL254320A0
IL254320A0 IL254320A IL25432017A IL254320A0 IL 254320 A0 IL254320 A0 IL 254320A0 IL 254320 A IL254320 A IL 254320A IL 25432017 A IL25432017 A IL 25432017A IL 254320 A0 IL254320 A0 IL 254320A0
Authority
IL
Israel
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
IL254320A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IL254320A0 publication Critical patent/IL254320A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL254320A 2015-03-20 2017-09-04 organic compounds IL254320A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135915P 2015-03-20 2015-03-20
PCT/US2016/023198 WO2016154027A1 (en) 2015-03-20 2016-03-18 Organic compounds

Publications (1)

Publication Number Publication Date
IL254320A0 true IL254320A0 (en) 2017-11-30

Family

ID=56977765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254320A IL254320A0 (en) 2015-03-20 2017-09-04 organic compounds

Country Status (13)

Country Link
US (1) US10188758B2 (enExample)
EP (1) EP3270920B1 (enExample)
JP (1) JP6726200B2 (enExample)
KR (1) KR20170129906A (enExample)
CN (1) CN107405339A (enExample)
AU (1) AU2016235483A1 (enExample)
BR (1) BR112017020135A2 (enExample)
CA (1) CA2978668A1 (enExample)
ES (1) ES2819833T3 (enExample)
IL (1) IL254320A0 (enExample)
MX (1) MX2017012022A (enExample)
RU (1) RU2017134796A (enExample)
WO (1) WO2016154027A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3339304A1 (en) 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物
EP3873902A1 (en) * 2018-11-02 2021-09-08 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU2003287023A1 (en) * 2002-11-05 2004-06-03 Eli Lilly And Company 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
WO2007010082A1 (en) * 2005-07-15 2007-01-25 Fermion Oy Process for preparing a 3-aryloxy-3-arylpropylamine
CA2661187A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
EP2161998B1 (en) * 2007-06-04 2015-09-02 Intra-Cellular Therapies, Inc. Pyridine derivatives as NET/SERT modulators
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US9352218B2 (en) 2009-04-21 2016-05-31 Nintendo Co., Ltd. Game apparatus and computer-readable storage medium

Also Published As

Publication number Publication date
EP3270920B1 (en) 2020-06-17
BR112017020135A2 (pt) 2018-05-29
EP3270920A4 (en) 2018-10-24
RU2017134796A (ru) 2019-04-04
KR20170129906A (ko) 2017-11-27
ES2819833T3 (es) 2021-04-19
US20180099060A1 (en) 2018-04-12
WO2016154027A1 (en) 2016-09-29
MX2017012022A (es) 2018-01-30
JP2018508556A (ja) 2018-03-29
US10188758B2 (en) 2019-01-29
CN107405339A (zh) 2017-11-28
AU2016235483A1 (en) 2017-10-12
CA2978668A1 (en) 2016-09-29
EP3270920A1 (en) 2018-01-24
JP6726200B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
IL272249A (en) organic compounds
IL272252A (en) organic compounds
IL261446A (en) organic compounds
IL248183A0 (en) organic compounds
IL248109A0 (en) organic compounds
GB201510019D0 (en) Compounds
IL252578A0 (en) organic compounds
GB201508747D0 (en) Compounds
GB201514754D0 (en) Compounds
GB201514751D0 (en) Compounds
GB201518365D0 (en) Compounds
GB201520419D0 (en) Compounds
GB201508864D0 (en) Compounds
IL254320A0 (en) organic compounds
IL252579A0 (en) organic compounds
GB201415838D0 (en) Organic compounds
GB201521758D0 (en) Organic compounds
GB201412979D0 (en) Organic compounds
GB201501824D0 (en) Organic compounds
GB201501115D0 (en) Compounds
GB201720380D0 (en) Organic compounds
GB201718491D0 (en) Organic compounds
GB201615797D0 (en) Organic compounds
GB201607404D0 (en) Organic compounds
GB201508857D0 (en) Compounds